Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

India Develops Effective COVID Treatment for Under $3 Per Person While America Remains in Vaccine Frenzy


Here in America, health bureaucrats keep parroting that the mRNA COVID vaccines are the only way out of this pandemic.

Despite the horrific side effects that I’ve repeatedly mentioned, millions of Americans have lined up for their jabs.

Roughly a month into the vaccine rollout, America’s daily case & death rates remain higher than the spring of 2020.

By comparison, India has done much better combatting the virus.

Take a look at this chart:

If you browse through India’s profile on Worldometer, their daily case & death rates have been steadily declining for months.

While India does have the 2nd most total COVID cases, keep in mind they have a population 4x the size of America.

When comparing the two country’s deaths per 1 million, it paints a different story.

USA = 11th highest

India = 103rd highest 

*Numbers as of 1/18/21*

What could explain the drastic difference?

An affordable, but effective home COVID Kit might be the answer:

Seeing how India’s numbers have declined, why hasn’t this home treatment been passed out to Americans nationwide?

A home Covid kit could have been passed out to every positive case for a fraction of the money in the recent stimulus package.

Big Pharma has to reap in their vaccine profits though.

And suppress any other viable treatment option from the American people.

Life Site News gave additional details on the kit:

While the United States continues its aggressive military roll-out of novel, expensive and dangerous pharmaceutical vaccines, India has developed a “miraculously” effective and safe COVID-19 treatment kit which costs merely $2.65 per person and has helped put the nation’s case and fatality rates in “steep decline.”

Last month, several medical experts testified before the U.S. Senate Homeland Security Committee in favor of authorizing ivermectin for early treatment of the novel coronavirus. Among them, Dr. Pierre Kory, founding member of Front Line Covid-19 Critical Care Alliance (FLCCC), explained that ivermectin, a Nobel Prize–winning anti-parasitic agent, “basically obliterates transmission of this virus,” with “miraculous effectiveness.”

Ivermectin has been the subject of dozens of studies and anecdotal success stories since it was found to reduce COVID-19 in a laboratory last June.

“I’ve been treating COVID pretty much every single day since the onset,” Kory said. “When I say ‘miracle’ I do not use that term lightly…that is a scientific recommendation based on mountains of data that has emerged in the last three months.”

FLCCC has developed a treatment regimen incorporating ivermectin, which the group claims has led to up to 83% lower-than-average COVID-19 death rates in hospitals that have applied it.

However, the Food and Drug Administration (FDA) has refused emergency authorization of ivermectin to treat coronavirus, stating for months that “[m]ore testing is needed.”

In contrast, on the other side of the world, India has embraced the treatment protocol specified by Dr. Kory and his colleagues and is now manufacturing this product under the brand name “Ziverdo Kit” and it only costs approximately $2.65 per person.

Though the U.S. National Institutes of Health (NIH) recommends no treatment for those suffering from SARS-COV-2 “unless the patient is hospitalized and requires oxygen,” in India, they began treating coronavirus patients early, including the use of hydroxychloroquine (HCQ).

Dr. Makarand Paranjpe and his wife, both 77 year-old Indian physicians, fully recovered from the COVID-19 virus using early treatment last November, TrialSiteNews (TSN) reports. She used hydroxychloroquine, and he took ivermectin.

“Without any treatment, we know that the virus enters the cells and replicates there,” Paranjpe said. “They can create disease that gets much more severe.” Stopping such replication as early as possible is the simple function of these inexpensive and safe treatments.

Last March, as debates raged in the U.S. over the merits of HCQ, following President Trump’s endorsement of the drug, India had already recommended it in its national guidelines affirming it “should be used as early in the disease course as possible…and should be avoided in patients with severe disease.”

99.9% Fine Silver MAGA Collector Coins!

Following the June discovery of ivermectin’s efficacy in treating the virus, along with significant subsequent testing, the largest state in their nation, Uttar Pradesh (UP) (pop. 230 million), announced in August that it was replacing their HCQ protocol with ivermectin for the prevention and treatment of COVID-19.

“By the end of 2020, Uttar Pradesh — which distributed free ivermectin for home care — had the second-lowest fatality rate in India at 0.26 per 100,000 residents in December. Only the state of Bihar, with 128 million residents, was lower, and it, too, recommends ivermectin,” writes Mary Beth Pfeiffer of TSN.

By further comparison, utilizing early treatment with HCQ and ivermectin, the densely populated India, which has four times the population of the U.S., has less than half of the coronavirus related deaths. “And India isn’t just beating the poorly performing U.S. In all, 98 nations have higher death rates than India,” Pfeiffer writes.

Dr. Anil K. Chaurasia, a physician in UP, affirmed that starting in mid-September, “a clear decline in COVID cases and fatalities in India was noticeable … [and the] “steep decline in cases and fatalities is still continuing.”

The same results hold for neighboring Bangladesh, one of the most densely populated nations in the world, where doctors also utilize an ivermectin home care therapy, and they have an even lower fatality rate, ranking 128thin the world.

Kory cited similar results in Peru, Argentina, Brazil and several other South American countries demonstrating the effectiveness of ivermectin.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!